Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
Allergy
; 71(7): 1057-61, 2016 07.
Article
en En
| MEDLINE
| ID: mdl-27008542
ABSTRACT
The effects of allergen immunotherapy (AIT) on local allergic rhinitis (LAR) are largely unknown. We conducted the first randomized, double-blind, placebo-controlled (DBPC), phase II trial of D. pteronyssinus (DP) subcutaneous AIT (DP-AIT) on LAR (clinicaltrials.gov identifier NCT02123316). Thirty-six LAR patients received Pangramin PLUS DP or placebo for 24 months. The primary endpoints were symptoms, medication scores, and medication-free days. The secondary included skin test, serum specific IgE and IgG4, nasal allergen provocation test (NAPT), and adverse events. AIT-DP produced significant improvements in both primary and secondary endpoints vs placebo. After 12 months of AIT-DP, we detected a significant and marked increase in allergen tolerance with negative NAPT in 50% of patients, and significant increases of serum sIgG4. Immunotherapy was well tolerated; no systemic reactions were reported. This study demonstrated that AIT-DP is a safe and clinically effective treatment for LAR, confirming that LAR is a new indication for AIT.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Alérgenos
/
Desensibilización Inmunológica
/
Dermatophagoides pteronyssinus
/
Antígenos Dermatofagoides
/
Rinitis Alérgica
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Allergy
Año:
2016
Tipo del documento:
Article
País de afiliación:
España